BioAtla will present research on Mecbotamab Vedotin at the IASLC meeting December 14, 2024, in Washington, DC.
Quiver AI Summary
BioAtla, Inc., a clinical-stage biotechnology company specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, announced that it will present a poster at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting in Washington, DC, from December 13–15, 2024. The poster, titled "Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin," will be presented by a team of researchers on December 14, 2024. BioAtla is advancing its CAB technology to develop innovative antibody-drug conjugates, with two programs currently in Phase 2 clinical testing. The company holds extensive patent coverage for its CAB products and technologies. Additional information and presentation materials will be available on BioAtla's website following the event.
Potential Positives
- BioAtla is set to present significant clinical research findings on mecbotamab vedotin at a prominent international conference, highlighting its involvement in cutting-edge cancer treatment developments.
- The company's proprietary CAB technology offers a unique approach to antibody therapeutics with the potential for increased efficacy and reduced toxicity, making its products more competitive in the biotech market.
- BioAtla holds extensive patent coverage with over 780 active patent matters, reinforcing its innovation and potential to maintain a strong market position in the biotechnology field.
- The ongoing Phase 2 clinical testing of two first-in-class CAB programs demonstrates BioAtla's commitment to advancing innovative therapies, which can attract investment and partnership opportunities.
Potential Negatives
- Company is still in clinical stages and has not yet achieved significant commercial milestones, which may raise concerns about its viability and future prospects.
- There is no mention of positive data or results concerning their ongoing clinical trials, potentially suggesting challenges in their drug development process.
- Dependence on external relationships, such as with BioDuro-Sundia for operations in China, may introduce risks related to collaboration and operational control.
FAQ
What is BioAtla, Inc. known for?
BioAtla, Inc. is a biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors.
When is BioAtla's poster presentation scheduled?
The poster presentation is scheduled for Saturday, December 14, 2024, from 5:40 P.M. to 6:40 P.M. ET.
What will BioAtla present at the IASLC meeting?
BioAtla will present research on the KRAS genotype and clinical outcomes in patients with advanced NSCLC treated with Mecbotamab Vedotin.
How can I access BioAtla's presentation materials?
A copy of the presentation materials will be available in the "Publication" section of BioAtla's website after the presentation.
Where are BioAtla's operations based?
BioAtla has operations in San Diego, California, and Beijing, China, through its partnership with BioDuro-Sundia.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BCAB Hedge Fund Activity
We have seen 23 institutional investors add shares of $BCAB stock to their portfolio, and 81 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 1,383,836 shares (-35.5%) from their portfolio in Q3 2024
- CORMORANT ASSET MANAGEMENT, LP removed 1,170,870 shares (-100.0%) from their portfolio in Q2 2024
- MILLENNIUM MANAGEMENT LLC added 1,010,327 shares (+61.3%) to their portfolio in Q3 2024
- DEUTSCHE BANK AG\ removed 670,000 shares (-56.1%) from their portfolio in Q3 2024
- AQR CAPITAL MANAGEMENT LLC removed 636,136 shares (-100.0%) from their portfolio in Q3 2024
- SCION ASSET MANAGEMENT, LLC removed 633,959 shares (-100.0%) from their portfolio in Q3 2024
- TANG CAPITAL MANAGEMENT LLC removed 500,000 shares (-36.4%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming International Association for the Study of Lung Cancer (IASLC) 2024 Hot Topic in Basic & Translational Science Meeting to be held in Washington, DC from December 13–15, 2024.
Presentation Details:
| Title: | Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, a CAB-AXL-ADC | |
| Authors: | Julia Rotow, Grace K. Dy, Edwin Yau, Elaine Shum, Mariam Alexander, Karen L. Reckamp, Roland Leung, Dariusz M. Kowalski, Jose Fuentes Pradera, Jon Zugazagoitia Fraile, Kyechin Chen, Kartik Aysola, D. Ross Camidge | |
| Poster Number: | PP01.03 | |
| Session Type: | Poster Reception | |
| Session Date and Time: | Saturday, December 14, 2024 from 5:40 P.M. – 6:40 P.M. ET |
A copy of the presentation materials can be accessed on the “ Publication ” section of the Company’s website at www.bioatla.com once the presentation has concluded.
About BioAtla®, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAB technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The company’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. To learn more about BioAtla, Inc. visit www.bioatla.com .
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
/A%20photo%20of%20a%20Sandisk%20Solid%20State%20Drive%20by%20Top%20Popular%20Vector%20by%20Shutterstock.jpg)
/AI%20(artificial%20intelligence)/Data%20Center%20by%20Caureem%20via%20Shutterstock%20(2).jpg)
/ServiceNow%20Inc%20building%20in%20Silicon%20Valley-by%20Sundry%20Photography%20via%20iStock.jpg)